Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERCC6
REST API REST API
Homo sapiens
ERCC6 is differentially expressed in 216 experiments: 85 organism parts: blood, cervix, ... (83 more);, 114 disease states: normal, adenocarcinoma, ... (112 more);, 72 cell types 259 cell lines 31 compound treatments and 67 other conditions.
Synonyms CSB, RAD26, CKN2
Orthologs RAD26 (Saccharomyces cerevisiae)   ercc6 (Danio rerio)   ERCC6 (Bos taurus)   Ercc6 (Mus musculus)   ERCC6 (Gallus gallus)   Ercc6 (Rattus norvegicus)   pgbd3 (Xenopus laevis)   ERCC6 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, response to oxidative stress, DNA binding, nucleotide-excision repair, protein binding, DNA repair, DNA damage response, signal transduction resulting in induction of apoptosis, response to toxin, protein N-terminus binding, nucleic acid binding, activation of JNKK activity, transcription from RNA polymerase II promoter, photoreceptor cell maintenance, soluble fraction, ATP binding, activation of JUN kinase activity, DNA-dependent ATPase activity, nucleus, transcription elongation factor complex, nucleotide binding, chromatin binding, hydrolase activity, protein C-terminus binding, nucleoplasm, base-excision repair, response to DNA damage stimulus, response to gamma radiation, response to X-ray, nucleolus, helicase activity, pyrimidine dimer repair, transcription-coupled nucleotide-excision repair, response to superoxide, response to UV-B, protein complex binding, regulation of transcription elongation, DNA-dependent, positive regulation of transcription elongation, DNA-dependent
InterPro Term SNF2_N, Helicase_C, DEAD-like_helicase
UniProt Accession D6R9X7, Q03468, Q68DI2, F5H1J0, F5H493
Gene-Disease Assocation LUNG CANCER, DE SANCTIS-CACCHIONE SYNDROME, COCKAYNE SYNDROME, TYPE B; CSB, CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1, MACULAR DEGENERATION, AGE-RELATED, 5; ARMD5, UV-SENSITIVE SYNDROME; UVS
Search EB-eye ENSG00000225830
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, E-GEOD-6919, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
primary culture
2
E-GEOD-2450, E-GEOD-1657
SUM159PT
1
E-MTAB-62
HS578T
1
E-MTAB-62
PC-3MM2
1
E-MEXP-2172
KB/CP
1
E-GEOD-19397
253 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21612, E-GEOD-21668, E-GEOD-13909, ... (40 experiments)

Factor Value U/D Experiments
CD34+
2
E-TABM-145, E-AFMX-5
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
primary T lymphocytes
1
E-GEOD-13909
leydig cell
1
E-MTAB-25
spheroid
1
E-GEOD-21612
bronchial epithelial
1
E-AFMX-5
66 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-2069, E-GEOD-22148, ... (31 experiments)

Factor Value U/D Experiments
colorectal adenocarcinoma
1
E-MTAB-37
lung large cell carcinoma
1
E-MTAB-62
T cell acute lymphoblastic leukemia
1
E-MTAB-62
cMCL (conventional mantle cell lymphoma)
1
E-GEOD-16455
carcinoma in situ, bladder tumor
1
E-MTAB-62
B-cell neoplasm
1
1
E-MTAB-37
108 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-TABM-782, ... (21 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-412, E-GEOD-5824, E-GEOD-7307, E-MEXP-1958, E-GEOD-20719, ... (7 experiments)
endotoxin
1
E-GEOD-3026
MIG control
1
E-GEOD-15811
dimethyl sulfoxide
1
E-GEOD-5824
valproic acid
1
E-GEOD-1615
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
25 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-21610 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-19246, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-6431, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-22593, E-TABM-321, E-TABM-868, E-TABM-601, E-GEOD-17347 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-2657, E-GEOD-12773, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-TABM-15, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765, E-GEOD-21612

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Processing time: 0.264 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM